Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

NCT06119217 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

COMBINATION_PRODUCT: TTX-030, nab-paclitaxel and gemcitabine
COMBINATION_PRODUCT: TTX-030, budigalimab, nab-paclitaxel and gemcitabine
COMBINATION_PRODUCT: Nab-Paclitaxel and gemcitabine

Sponsor

Trishula Therapeutics, Inc.

Collaborators

[object Object]